Statute Details
- Title: Health Products (Composition of Offences) Regulations 2011
- Act Code: HPA2007-S542-2011
- Type: Subsidiary Legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D)
- Enacting Authority: Health Sciences Authority (with Minister for Health’s approval)
- Commencement: 3 October 2011
- Key Provisions: Regulation 1 (citation/commencement); Regulation 2 (compoundable offences); Regulation 3 (amendment/deletion)
- Current Version: Current version as at 27 Mar 2026 (with amendments including S 540/2016, S 150/2021, S 832/2023)
- Compounding Mechanism Reference: Section 65 of the Health Products Act (as invoked by Regulation 2)
What Is This Legislation About?
The Health Products (Composition of Offences) Regulations 2011 (“Composition Regulations”) is a procedural instrument that enables certain offences under the Health Products Act and related health product regulations to be “compounded” rather than prosecuted in court. In plain language, it creates a framework under which the regulator (the Health Sciences Authority, through the Chief Executive and authorised officers) can offer an administrative settlement for specified regulatory breaches.
Compounding is a common enforcement tool in Singapore regulatory practice. Instead of taking every contravention through the criminal justice system, the law identifies categories of offences that are suitable for settlement. This can reduce enforcement delays, focus prosecutorial resources on more serious or repeat conduct, and provide regulated entities with a clearer path to resolve compliance failures.
Although the Regulations are short, they are highly consequential in practice because they determine which offences are eligible for compounding and therefore affect compliance strategy, risk management, and how enforcement outcomes are negotiated.
What Are the Key Provisions?
Regulation 1 (Citation and commencement) confirms that the Regulations may be cited as the Health Products (Composition of Offences) Regulations 2011 and that they came into operation on 3 October 2011. This is important for determining the time period during which the compounding eligibility applies.
Regulation 2 (Compoundable offences) is the core provision. It states that the following offences may be compounded in accordance with section 65 of the Health Products Act by the Chief Executive or any officer of the Authority authorised in writing by the Chief Executive. The use of “may” indicates discretion: compounding is not automatic even where an offence falls within the listed categories.
Regulation 2 then sets out a detailed list of compoundable offences across multiple regulatory regimes. These include offences under the Health Products Act itself (for example, offences tied to specified sections such as section 12(6)(a), 13(6)(a), 14(4), 15(2), 16(2)(a), 17(3), 18(2), 19(2), 20(3), 21(3), 23(3)(a), 35(4), 36(5), 40(3), 41(2), 42(5)(a), 43(3), 44(3)(a), 49(5)(e), (9) or (11), 50, and 66(4)). The list is not merely illustrative; it is exhaustive for the offences that the Regulations deem suitable for compounding.
Beyond the Act, Regulation 2 also identifies compoundable offences under a series of subsidiary regulations governing different categories of health products. The Regulations therefore operate as a “cross-regime” compounding eligibility map. Key examples from the extract include:
(a) Active Ingredients: an offence under section 47(4) of the Act relating to a contravention of the Health Products (Active Ingredients) Regulations 2023, except offences relating to contraventions of regulation 4 or 5 of those Active Ingredients Regulations. This carve-out signals that certain active ingredient requirements are treated as too sensitive or serious for compounding (at least under this instrument).
(b) Cosmetic Products: an offence under regulation 4(3), 10(3) or 11(4)(a) of the Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations 2007 is compoundable. This suggests that particular compliance failures within the ASEAN Cosmetic Directive framework are eligible for administrative settlement.
(c) Medical Devices: an offence under specified provisions of the Health Products (Medical Devices) Regulations 2010 is compoundable, including offences under regulation 13A(3), 31(5), 32(2), 36A(5), 37, 38(3), 39(3), 39A(3), 39B(3), 40(2), 41(3), 43(2), 44(4), 45(3), 46(4), 47(3), 48(6) or (7)(b) or 49(5) or (6)(b). The Regulations were amended in 2016 (S 540/2016) to add or refine this list, reflecting evolving enforcement priorities as the medical devices regulatory framework developed.
(d) Therapeutic Products: offences under specified provisions of the Health Products (Therapeutic Products) Regulations 2016 are compoundable, including offences under regulation 21(4), 31(3), 32(4), 33(3), 40, 41(6) or (7)(b), 42(4) or (5)(b), 43(2), 44(3), 45(2), 46(8), 48(7) or 65(3). Again, the list is granular, indicating that not all therapeutic product breaches are treated equally for compounding purposes.
(e) Licensing of Retail Pharmacies: an offence under regulation 7(5) of the Health Products (Licensing of Retail Pharmacies) Regulations 2016 is compoundable.
(f) Advertisement of Specified Health Products: an offence under regulation 15(2) of the Health Products (Advertisement of Therapeutic Products) Regulations 2016—renamed as the Health Products (Advertisement of Specified Health Products) Regulations 2016 from 1 March 2021—is compoundable. This illustrates how the compounding eligibility list can track regulatory renaming and scope changes over time.
(g) Clinical Trials: an offence under regulation 29(1)(a) of the Health Products (Clinical Trials) Regulations 2016 is compoundable, but only in respect of contraventions of a long set of specified sub-regulations (e.g., regulation 4(4) or (6), 5(1)–(6), 6, 7(2), 8(1), 9(1), 10(1), (2), (4) or (6), and many others). This structure indicates that compounding is available for certain clinical trial compliance breaches, but only where the underlying contravention falls within the enumerated list.
(h) Clinical Research Materials: offences under regulation 24(1)(a) of the Health Products (Therapeutic Products as Clinical Research Materials) Regulations 2016 (renamed as the Health Products (Clinical Research Materials) Regulations 2016 from 1 March 2021) are compoundable.
(i) Oral Dental Gums: offences under specified provisions of the Health Products (Oral Dental Gums) Regulations 2016 are compoundable.
(j) Cell, Tissue and Gene Therapy Products: offences under specified provisions of the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 are compoundable.
Finally, Regulation 3 (Amendment of Health Products (Medical Devices) Regulations 2010) deletes regulation 51 of the Medical Devices Regulations 2010. While the extract does not reproduce the deleted text, the deletion indicates that the earlier compounding-related or procedural provision in the medical devices regime was superseded by the 2011 compounding regulations (or was otherwise rendered unnecessary). For practitioners, this is a reminder to check whether a deleted provision affects transitional enforcement or the interpretation of older compliance obligations.
How Is This Legislation Structured?
The Regulations consist of three regulations only:
Regulation 1 sets out the citation and commencement date.
Regulation 2 provides the substantive list of offences that are eligible for compounding under section 65 of the Health Products Act. It is structured as a set of enumerated categories (a) through (j), spanning offences under the Act and multiple sector-specific health product regulations.
Regulation 3 makes a consequential amendment by deleting a specific regulation in the Medical Devices Regulations 2010.
Who Does This Legislation Apply To?
In practical terms, the Regulations apply to regulated persons and entities that may commit offences under the Health Products Act and its subsidiary regulations—such as manufacturers, importers, distributors, retailers, clinical trial sponsors/investigators (as applicable), and other regulated stakeholders in the health product supply chain.
Because Regulation 2 is drafted by reference to specific offence provisions, the scope is not defined by a general “class of persons” clause. Instead, eligibility for compounding depends on whether the alleged conduct falls within one of the listed offence provisions. Where it does, the Authority has discretion to compound; where it does not, the matter may proceed through prosecution or other enforcement pathways under the Act.
Why Is This Legislation Important?
For practitioners, the main significance of the Composition Regulations is that they directly affect enforcement outcomes. If an offence is compoundable, the regulator may offer settlement, which can reduce legal costs, avoid criminal proceedings, and provide a faster resolution. Conversely, if an offence is excluded (for example, the carve-out for certain Active Ingredients Regulations breaches), the entity faces a higher enforcement risk and may need to prepare for prosecution.
Second, the Regulations provide a compliance risk map. The granular listing of compoundable offences across multiple product categories helps counsel advise clients on which regulatory breaches are more likely to be handled administratively. This can inform internal compliance audits, training priorities, and the allocation of resources to mitigate the most enforcement-sensitive obligations.
Third, the Regulations demonstrate how Singapore’s health product regulatory framework evolves. The amendments noted in the timeline (S 540/2016, S 150/2021, S 832/2023) show that compounding eligibility is updated as new product categories and regulatory regimes are introduced (e.g., Active Ingredients 2023; Cell, Tissue and Gene Therapy Products 2021) and as existing regimes are renamed or restructured (e.g., advertisement regulations from 1 March 2021). Practitioners should therefore treat the Regulations as a living instrument and verify the current version when advising on compounding feasibility.
Related Legislation
- Health Products Act (Cap. 122D) — in particular, section 65 (compounding) and the offence provisions referenced in Regulation 2
- Health Products (Medical Devices) Regulations 2010 (G.N. No. S 436/2010)
- Health Products (Active Ingredients) Regulations 2023 (G.N. No. S 831/2023)
- Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations 2007 (G.N. No. S 683/2007)
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016)
- Health Products (Licensing of Retail Pharmacies) Regulations 2016 (G.N. No. S 330/2016)
- Health Products (Advertisement of Therapeutic Products) Regulations 2016 (renamed as from 1 March 2021)
- Health Products (Clinical Trials) Regulations 2016 (G.N. No. S 331/2016)
- Health Products (Clinical Research Materials) Regulations 2016 (renamed from 1 March 2021)
- Health Products (Oral Dental Gums) Regulations 2016 (G.N. No. S 539/2016)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021)
Source Documents
This article provides an overview of the Health Products (Composition of Offences) Regulations 2011 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.